On August 10, Harrow Inc. (NASDAQ:HROW) walked investors through a first half that fell short and a back half that now has to make up the difference. Revenue for the first six months of 2026 came in around $115 million, lighter than management had expected, largely because of pricing changes tied to VEVYE. Yet the […]

Revenue hit $70.7M with guidance raised to $350M-$365M for full year.

According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent […]

Harrow (NasdaqGM:HROW) announced the launch of BYOOVIZ in the retinal biosimilar market, adding a new product to its ophthalmology lineup. The company reported expanded formulary coverage for VEVYE, increasing potential patient access to its dry eye disease treatment. Harrow acquired TYRVAYA, further building out its portfolio focused on dry eye disease. This cluster of product moves and acquisitions around eye care is part of a wider push across healthcare, and investors who follow Harrow...

Harrow Inc (HROW) reports strong Q2 2026 with record IHISO and Vevi demand, reiterates full-year guidance, and outlines accretive Tervaya acquisition synergies.

Harrow (NASDAQ:HROW) reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half of 2026 with stronger demand across several products, improved pricing and expanded commercial infras

Moby summary of Harrow Health, Inc.'s Q2 2026 earnings call

Harrow (HROW) delivered earnings and revenue surprises of -47.83% and -0.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ironwood (IRWD) delivered earnings and revenue surprises of +19.23% and -5.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?